{"id":32554,"date":"2025-06-27T17:39:00","date_gmt":"2025-06-27T12:09:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32554"},"modified":"2025-06-26T14:40:13","modified_gmt":"2025-06-26T09:10:13","slug":"spinal-cord-injury-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape","title":{"rendered":"The Spinal Cord Injury Treatment Landscape: Limited Progress, Immense Potential"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e1002821287\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e1002821287\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape\/#STEMIRAC_Stands_Alone_The_Only_Approved_SCI_Treatment_in_Japan\" >STEMIRAC Stands Alone: The Only Approved SCI Treatment in Japan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape\/#SCI_Treatment_Space_Heats_Up_with_Growing_Pipeline_Activity\" >SCI Treatment Space Heats Up with Growing Pipeline Activity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape\/#Recent_Developments_in_Spinal_Cord_Injury_Treatment_Space\" >Recent Developments in Spinal Cord Injury Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape\/#SCI_Treatment_Market_to_Maintain_Upward_Momentum_Through_2034\" >SCI Treatment Market to Maintain Upward Momentum Through 2034<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Every year, thousands of lives are changed in an instant by spinal cord injuries\u2014yet most people know surprisingly little about them. Spinal cord injury refers to the abrupt damage to the spinal cord&#8217;s nerve tissue resulting from trauma, illness, or degenerative conditions. The impact can differ, often leading to upper or lower motor neuron damage and resulting in disruptions to motor, sensory, and autonomic functions, which can be either short-term or lasting.<\/p>\n\n\n\n<p><em>According to DelveInsight, there were approximately <\/em><strong><em>45,000<\/em><\/strong><em> <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-injury-epidemiology-forecast\"><em>incident cases of spinal cord injury<\/em><\/a><em> and around <\/em><strong><em>960,000<\/em><\/strong><em> diagnosed prevalent cases across the 7MM in 2024. These figures are expected to increase by 2034. The United States accounted for the highest number of diagnosed prevalent SCI cases among the 7MM in 2024, as per DelveInsight&#8217;s estimates.<\/em><\/p>\n\n\n\n<p>Management of spinal cord injury focuses on stabilizing the injury, supporting functional recovery, and improving outcomes through a combination of medical treatment, surgical intervention, and rehabilitation. Core objectives include controlling pain, enhancing mobility, and fostering patient independence.&nbsp;<\/p>\n\n\n\n<p>However, the absence of curative therapies and the reliance on symptomatic treatment limit long-term progress. Moreover, current clinical practices lack real-time monitoring of the spinal cord, raising the risk of undetected complications that can worsen the condition during the acute phase.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-stemirac-stands-alone-the-only-approved-sci-treatment-in-japan\"><span class=\"ez-toc-section\" id=\"STEMIRAC_Stands_Alone_The_Only_Approved_SCI_Treatment_in_Japan\"><\/span><strong>STEMIRAC Stands Alone: The Only Approved SCI Treatment in Japan<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The treatment approach for spinal cord injury primarily focuses on rapid medical intervention, surgery, and rehabilitation. In the initial or acute stage, surgical decompression is commonly performed to relieve pressure on the spinal cord, often by removing bone fragments or herniated discs.<\/p>\n\n\n\n<p>Pharmacological therapies also play a key role. Intravenous methylprednisolone may be administered soon after injury to minimize inflammation and nerve damage, although its widespread use remains controversial due to potential adverse effects. Other drugs with anti-inflammatory or neuroprotective properties are employed to mitigate secondary damage.<\/p>\n\n\n\n<p>Rehabilitation involves physical therapy to restore mobility and strength, along with the use of assistive technologies such as wheelchairs and braces to support everyday activities. Chronic pain is managed through medications like tramadol, gabapentin, and cannabinoids. However, a definitive cure for SCI has yet to be found.<\/p>\n\n\n\n<p>Currently, <strong>LYRICA (pregabalin) <\/strong>is the only medication approved by the US FDA for neuropathic pain linked to SCI, and generic alternatives are available. Another <a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-injury-market\">spinal cord injury treatment<\/a> is <strong>STEMIRAC<\/strong>, an autologous mesenchymal stem cell therapy developed by <strong>Nipro Corporation<\/strong>. It involves extracting, culturing, and cryopreserving the patient\u2019s own bone marrow-derived stem cells, which are later infused intravenously. This therapy supports tissue repair, reduces inflammation, and aids recovery through immunomodulatory effects and secretion of supportive factors.<\/p>\n\n\n\n<p>STEMIRAC received conditional approval in 2018 from Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of neurological symptoms following traumatic SCI. This approval came with a seven-year post-marketing surveillance requirement to confirm long-term safety and effectiveness. Ongoing efforts aim to accelerate its full-scale clinical implementation, with full approval anticipated by December 2025.<\/p>\n\n\n\n<p>In July 2023, Nipro Corporation launched a clinical trial targeting chronic SCI, aiming to expand STEMIRAC&#8217;s use beyond the subacute phase. This move is intended to speed up commercialization and make the therapy more accessible to a broader patient population.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/spinal-cord-injury-market\"><img decoding=\"async\" width=\"1024\" height=\"531\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-1024x531.png\" alt=\"Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance\" class=\"wp-image-32559\" style=\"width:840px;height:auto\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-1024x531.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-300x156.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-150x78.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-768x398.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-1536x797.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143807\/Spinal-Cord-Injury-Therapeutics-Market-At-a-Glance-2048x1062.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sci-treatment-space-heats-up-with-growing-pipeline-activity\"><span class=\"ez-toc-section\" id=\"SCI_Treatment_Space_Heats_Up_with_Growing_Pipeline_Activity\"><\/span><strong>SCI Treatment Space Heats Up with Growing Pipeline Activity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Currently, there are limited approved therapies specifically for spinal cord injury. To overcome this unmet need in the spinal cord injury treatment space, several companies are advancing their assets through various stages of development, driving innovation in the SCI treatment market. Their efforts are shaping a dynamic landscape and opening up significant opportunities for market growth and expansion.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-injury-pipeline-insight\">SCI treatment pipeline<\/a> continues to expand, featuring candidates such as <strong>Kringle Pharma\u2019s KP-100IT, Neuroplast\u2019s Neuro-Cells, Mitsubishi Tanabe Pharma America\u2019s MT-3921, AbbVie\u2019s Elezanumab, Pharmazz\u2019s PMZ-1620, Neurofix\u2019s NFX88, NervGen Pharma\u2019s NVG-291, ReNetX Bio\u2019s AXER-204, and NurExone\u2019s ExoPTEN<\/strong>, among others.<\/p>\n\n\n\n<p>Kringle Pharma (KP-100IT), an innovative therapy in advanced development, is in Phase III clinical trials and is anticipated to launch by 2025 in Japan for the treatment of SCI.<\/p>\n\n\n\n<p>The anticipated launch of these emerging therapies for SCI treatment are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SCI treatment market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-recent-developments-in-spinal-cord-injury-treatment-space\"><span class=\"ez-toc-section\" id=\"Recent_Developments_in_Spinal_Cord_Injury_Treatment_Space\"><\/span><strong>Recent Developments in Spinal Cord Injury Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>June 2025, \u0101shibio <\/strong>announced that the first patient had been dosed in its Phase 1b clinical trial of andecaliximab for spinal cord injury (SCI). The trial, named ANDECA-HO, is focused on assessing patients at risk of developing heterotopic ossification (HO)\u2014a disorder marked by abnormal bone growth in muscles, tendons, ligaments, and other soft tissues.<\/li>\n\n\n\n<li>In <strong>June 2025, Kringle Pharma, Inc.<\/strong> announced that the FDA had granted orphan drug designation (ODD) to KP-100IT, its intrathecal formulation of recombinant human hepatocyte growth factor (HGF), for treating the acute phase of spinal cord injury.<\/li>\n\n\n\n<li>In <strong>June 2025, NervGen Pharma Corp.<\/strong> announced positive topline results from the chronic cohort (1\u201310 years post-injury) of its Phase 1b\/2a clinical trial evaluating its lead candidate, NVG-291, for the treatment of spinal cord injury. NVG-291 achieved one of its co-primary endpoints and showed encouraging improvements in the GRASSP score, a tool specifically developed to measure hand function in people with cervical spinal cord injuries.<\/li>\n\n\n\n<li>In <strong>March 2025, NurExone Biologic Inc.<\/strong> announced the successful completion of a key preclinical study supporting its upcoming Investigational New Drug (IND) application. This milestone brings the company closer to initiating first-in-human trials. The study showed that ExoPTEN treatment, across various dosing regimens, led to motor function recovery and notably enhanced blood flow at the spinal cord injury site\u2014an essential element for tissue repair and functional improvement.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sci-treatment-market-to-maintain-upward-momentum-through-2034\"><span class=\"ez-toc-section\" id=\"SCI_Treatment_Market_to_Maintain_Upward_Momentum_Through_2034\"><\/span><strong>SCI Treatment Market to Maintain Upward Momentum Through 2034<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Advances in imaging technologies such as MRI, along with standardized assessment tools like the ASIA classification system, have enhanced the precision of spinal cord injury diagnosis and treatment planning; however, current clinical practices still lack real-time spinal cord monitoring, increasing the risk of undetected deterioration during the acute phase.&nbsp;<\/p>\n\n\n\n<p>Meanwhile, the scarcity of approved therapies highlights a significant market opportunity for innovative drugs, particularly as breakthroughs in regenerative medicine, such as stem cell therapy and gene editing, gain momentum. Additionally, the growing emphasis on neurorehabilitation and neuroplasticity opens avenues for developing more effective approaches to improve functional recovery in SCI patients.<\/p>\n\n\n\n<p>DelveInsight estimates that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-injury-market\">market size for SCI<\/a> in the 7MM is expected to grow from <strong>USD 350 million<\/strong> in 2024 with a significant<strong> <\/strong>CAGR by 2034. This growth is mainly driven by the rising prevalence of SCI, driven by increasing awareness and risk factors like traumatic injuries, aging populations, and advancements in diagnostic tools.<\/p>\n\n\n\n<p>However, the variability in SCI severity and location, the complexity of long-term rehabilitation regimens affecting patient adherence, and the high costs of therapy development, including research, clinical trials, and regulatory compliance, collectively complicate SCI treatment protocols, hinder standardization, reduce therapy effectiveness, and pose significant financial challenges, particularly for smaller companies, ultimately limiting spinal cord injury treatment market growth.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-injury-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook-1024x194.png\" alt=\"Spinal Cord Injury Market Outlook\" class=\"wp-image-32558\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143711\/Spinal-Cord-Injury-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Every year, thousands of lives are changed in an instant by spinal cord injuries\u2014yet most people know surprisingly little about them. Spinal cord injury refers to the abrupt damage to the spinal cord&#8217;s nerve tissue resulting from trauma, illness, or degenerative conditions. The impact can differ, often leading to upper or lower motor neuron damage [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32556,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19865,22584,16900,19863,22583,22582],"industry":[17225],"therapeutic_areas":[17241],"class_list":["post-32554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-sci-market","tag-sci-treatment","tag-spinal-cord-injury","tag-spinal-cord-injury-market","tag-spinal-cord-injury-pipeline","tag-spinal-cord-injury-treatment","industry-pharmaceutical","therapeutic_areas-musculoskeletal"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Spinal Cord Injury Treatment Void: Addressing Unmet Needs<\/title>\n<meta name=\"description\" content=\"To overcome unmet need in the spinal cord injury treatment space, companies are advancing their assets through various stages of development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spinal Cord Injury Treatment Void: Addressing Unmet Needs\" \/>\n<meta property=\"og:description\" content=\"To overcome unmet need in the spinal cord injury treatment space, companies are advancing their assets through various stages of development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-27T12:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143556\/spinal-cord-injury-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spinal Cord Injury Treatment Void: Addressing Unmet Needs","description":"To overcome unmet need in the spinal cord injury treatment space, companies are advancing their assets through various stages of development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Spinal Cord Injury Treatment Void: Addressing Unmet Needs","og_description":"To overcome unmet need in the spinal cord injury treatment space, companies are advancing their assets through various stages of development.","og_url":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-27T12:09:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143556\/spinal-cord-injury-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape","name":"Spinal Cord Injury Treatment Void: Addressing Unmet Needs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143556\/spinal-cord-injury-treatment-landscape.png","datePublished":"2025-06-27T12:09:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"To overcome unmet need in the spinal cord injury treatment space, companies are advancing their assets through various stages of development.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/spinal-cord-injury-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143556\/spinal-cord-injury-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143556\/spinal-cord-injury-treatment-landscape.png","width":466,"height":284,"caption":"spinal-cord-injury-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/26143556\/spinal-cord-injury-treatment-landscape-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SCI Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SCI Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spinal cord injury<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spinal Cord Injury Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spinal Cord Injury Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spinal Cord Injury Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">SCI Market<\/span>","<span class=\"advgb-post-tax-term\">SCI Treatment<\/span>","<span class=\"advgb-post-tax-term\">Spinal cord injury<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Injury Market<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Injury Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Injury Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jun 27, 2025","modified":"Updated on Jun 26, 2025"},"absolute_dates_time":{"created":"Posted on Jun 27, 2025 5:39 pm","modified":"Updated on Jun 26, 2025 2:40 pm"},"featured_img_caption":"spinal-cord-injury-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32554"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32554\/revisions"}],"predecessor-version":[{"id":32561,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32554\/revisions\/32561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32556"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32554"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32554"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}